Evidence map›Paper›PMID 28117843›Full record

Trial reportTranslational psychiatry2017

Neuroprotection after a first episode of mania: a randomized controlled maintenance trial comparing the effects of lithium and quetiapine on grey and white matter volume.

M Berk, O Dandash, R Daglas, S M Cotton, K Allott, A Fornito, C Suo, P Klauser, B Liberg, L Henry and 5 more

Erratum issuedOpen access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Translational psychiatry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 25 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 5 pooled it
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 5 syntheses or guidelines pooled it, 100 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Changes in the brain structural connectome after a prospective randomized clinical trial of lithium and quetiapine treatment in youth with bipolar disorder.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2021
    Trial
  8. Trial
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Overview of lithium's use: a nationwide survey.International journal of bipolar disorders · 2021
    Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

M BerkIMPACT Strategic Research Centre, School of Medicine, Deakin University, Geelong, VIC, Australia.
O DandashBrain and Mental Health Laboratory, School of Psychological Sciences, Monash Institute of Cognitive and Clinical Neurosciences, Monash University, Clayton, VIC, Australia.
R DaglasOrygen, The National Centre of Excellence in Youth Mental Health, Parkville, VIC, Australia.
S M CottonOrygen, The National Centre of Excellence in Youth Mental Health, Parkville, VIC, Australia.
K AllottOrygen, The National Centre of Excellence in Youth Mental Health, Parkville, VIC, Australia.
A FornitoBrain and Mental Health Laboratory, School of Psychological Sciences, Monash Institute of Cognitive and Clinical Neurosciences, Monash University, Clayton, VIC, Australia.
C SuoBrain and Mental Health Laboratory, School of Psychological Sciences, Monash Institute of Cognitive and Clinical Neurosciences, Monash University, Clayton, VIC, Australia.
P KlauserBrain and Mental Health Laboratory, School of Psychological Sciences, Monash Institute of Cognitive and Clinical Neurosciences, Monash University, Clayton, VIC, Australia.
B LibergDepartment of Psychiatry, Melbourne Neuropsychiatry Centre, University of Melbourne and Melbourne Health, Carlton South, VIC, Australia.
L HenryOrygen, The National Centre of Excellence in Youth Mental Health, Parkville, VIC, Australia.
C MacneilOrygen Youth Health Clinical Program, Parkville, VIC, Australia.
M HastyOrygen Youth Health Clinical Program, Parkville, VIC, Australia.
P McGorryOrygen, The National Centre of Excellence in Youth Mental Health, Parkville, VIC, Australia.
C PantelisFlorey Institute for Neuroscience and Mental Health, Kenneth Myer Building, Royal Parade, Parkville, VIC, Australia.
M YücelBrain and Mental Health Laboratory, School of Psychological Sciences, Monash Institute of Cognitive and Clinical Neurosciences, Monash University, Clayton, VIC, Australia.
Orygen Youth Health · AUUniversity of Melbourne · AUMonash University · AUDeakin University · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lithium and quetiapine are effective treatments for bipolar disorder, but their potential neuroprotective effects in humans remain unclear. A single blinded equivalence randomized controlled maintenance trial was conducted in a prospective cohort of first-episode mania (FEM) patients (n=26) to longitudinally compare the putative protective effects of lithium and quetapine on grey and white matter volume. A healthy control sample was also collected (n=20). Using structural MRI scans, voxel-wise grey and white matter volumes at baseline and changes over time in response to treatment were investigated. Patients were assessed at three time points (baseline, 3 and 12-month follow-up), whereas healthy controls were assessed at two time points (baseline and 12-month follow-up). Patients were randomized to lithium (serum level 0.6 mmol l

Indexed as

Antimanic AgentsAntipsychotic AgentsBipolar DisorderFemaleGray MatterHumansLithium CompoundsMaintenance ChemotherapyMaleNeuroprotective AgentsOrgan SizeQuetiapine FumarateSingle-Blind MethodWhite MatterYoung AdultAntimanic AgentsAntipsychotic AgentsLithium CompoundsNeuroprotective AgentsQuetiapine Fumarate

Identifiers

PMID28117843
PMCPMC5545739
OpenAlexW2581241207

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.